Submit Deal

Marc Dunoyer

CEO at ALEXION PHARMACEUTICALS INC

Manager

Deal Bio

Total Deals5

Valued Deals5

Total Value£35,797M

Avg. Deal Size£7,160M

Market Context

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

Expertise

Key Relationships (5)

Sort

Japan

Pharmaceuticals

PrivateAcquisitionJoint Venture

target

Daiichi Sankyo (trastuzumab Deruxtecan)

bidder

Astrazeneca

£5,258m

11 dealmakers

United States

Biotechnology

MajorityPublicAcquisitionCross Border

target

Alexion Pharmaceuticals

bidder

Astrazeneca

£29,441m

63 dealmakers

United States

Biotechnology

Cross BorderAcquisitionMajorityPrivate

target

Caelum Biosciences

bidder

Astrazeneca

£257m

10 dealmakers

United States

Biotechnology

DomesticPublicAcquisitionMajority

target

Logicbio Therapeutics

bidder

Alexion Pharmaceuticals

£60m

48 dealmakers

United States

Biotechnology

AcquisitionMajorityPrivateDomestic

target

Pfizer (preclinical Gene Therapy Programs)

bidder

Alexion Pharmaceuticals

£779m

14 dealmakers

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy